Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):326-335.
-
Gill RR, Barlow J, Jaklitsch MT, Schmidlin EJ, Hartigan PM, Bueno R. Image-guided video-assisted thoracoscopic resection (iVATS): Translation to clinical practice-real-world experience. J Surg Oncol. 2020 Jun; 121(8):1225-1232.
-
Lu S. Novel vaccine technology and the future of vaccine science. Hum Vaccin Immunother. 2014; 10(5):1143-6.
-
Caldwell S, Sima C, Jameson G, Fleck S, Weiss GJ. Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials. Am J Clin Oncol. 2013 Apr; 36(2):146-50.
-
Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ. Determinants of patient screen failures in Phase 1 clinical trials. Invest New Drugs. 2013 Jun; 31(3):774-9.
-
Usmani SZ, Chiosis G. HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S77-81.
-
Sadelain M, Rivière I, Wang X, Boulad F, Prockop S, Giardina P, Maggio A, Galanello R, Locatelli F, Yannaki E. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci. 2010 Aug; 1202:52-8.
-
Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007 Feb; 43(3):481-9.
-
Balsam LB, Robbins RC. Haematopoietic stem cells and repair of the ischaemic heart. Clin Sci (Lond). 2005 Dec; 109(6):483-92.
-
Burstein S, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. Arthritis Rheum. 2004 Dec; 50(12):4078-9; author reply 4079-80.